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Introduction Pediatric epilepsy is one of the common illness in children. Pediatric epilepsy 
has significant impact not only to the patient, but also to the care takers. 
Furthermore, the disease could potentially cause strain in the limited resources 
of the healthcare system which is preventable. 
Methods A search was conducted to review relevant published studies on factors 
affecting seizure control using PubMed/MEDLINE, Google Scholar and also 
Science Direct searching engines databases using keywords: paediatric seizure, 
seizure control, side effects, antiepileptic, adherence and quality of life. 
Results In this review, we found that many factors contribute to the pediatric epilepsy, 
namely; compliance, genetic, age, socioeconomic factors, parental health 
literacy and numbers and side effects of the medications.  Furthermore, there 
is certain factors that need to be explored in the future, such as unaddressed 
parental concern on treatment/medication, denial of disease and drug-drug 
interactions. 
Conclusions Factors that had been identified can be used in the prevention and control 
programs, while factors which is less studied should be further studied in the 
future. 
Keywords Paediatric seizure - seizure control - side effects - antiepileptic - factors -  
adherence - quality of life. 
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INTRODUCTION 
Epidemiology 
Epilepsy is one of the most common neurological 
non-communicable disease affecting approximately 
50 million people worldwide, of all age categories.1 
One of the subgroups of population affected by 
epilepsy is children.  In a population-based study 
around the world, incidence rates of epilepsy in 
childhood range from approximately 0.5 to 8 per 
1000 person-years.2,3,4,5 By studying the factors that 
contribute to the general control of seizure and the 
prevalence of disease, it will be very helpful to 
perform control and prevention activities in respect 
of child epidemiology.  
Epilepsy is a disorder of the brain 
characterized by an enduring predisposition to 
generate epileptic seizure and by the 
neurobiological, cognitive, psychological and social 
and social consequences of the disease. For a person 
to have epilepsy, he or she should have at least one 
epileptic seizure.  Epileptic seizure is defined as a 
transient occurrence of signs and/or symptoms due 
to abnormal excessive or synchronous neuronal 
activity in brain.6  
The epidemiology of epilepsy however, 
differs for children. For instance, the etiology of 
pediatric epilepsy maybe idiopathic, genetic, and 
more commonly due to cerebral malformation 
especially neuronal migrational disorder. Strokes 
and tumors which may cause epilepsy in adults are 
uncommon etiology in pediatric patients. 7 
 
Health Care Resources 
An Australian study finds that although the rate of 
total hospitalization due to pediatric epilepsy is 
lower than pediatric asthma, the cost of treatment of 
pediatric epilepsy will be more than treating 
pediatric asthma.8 Findings from Malaysian 
research suggest that, the cost of medication for 
pediatric epilepsy is high. Mean monthly cost for 
monotherapy was RM 24.00 while for the 
polytherapy is RM 45.40. 9 Therefore, 
understanding the disease response towards 
treatment would be beneficial for the healthcare 
workers providing treatments and other stakeholders 
associated with the healthcare.  
 
Response to seizure treatment 
The response rate towards antiepileptic treatment is 
generally quoted between 60-70%. Although the 
etiology and mechanism of epilepsy disease may 
differ between adult and children population, the 
response rate are the same.  Local data on the 
response of antiepileptic in children is very limited. 
Study by both Hasan et al and Ibrahim et al both 
suggest seizure control rate of the pediatric epilepsy 
patient is 70%.  However, it should be noted that 
both studies were conducted in Penang General 
Hospital’s Pediatric Clinic albeit 5 years apart. 
Another point that need to be taken into account is 
that the studies define seizure control in pediatric 
patients as fit-free for 2 months and does not follow 
according the International League against Epilepsy. 
Seizure control is defined as seizure free for 12 
months after therapy. 10 
 
Definition of Response to the treatment/ Seizure 
Control 
For the purpose of defining the seizure control, we 
referred definition from International League 
Against Seizure. The response rate and definition of 
seizure free is same for adult and children: 
 
• The definition of response to treatment is 
no seizure for at least 12 months or freedom 
from seizures or 3 times pre-intervention 
inter-seizure interval (determined from 
seizures occurring within 12 months), 
whichever longer.10 
 
For patients who had epilepsy surgery, the definition 
of seizure control would be freedom of seizure after 
12 months of surgery.11 
 
• Drug resistant epilepsy may be defined as 
failure of adequate trials of 2 tolerated and 
appropriately chosen and used antiepileptic 
schedules (either monotherapy or 
combination) to achieve sustained seizure 
freedom.10 
 
Thus, we can say that period of 12 months of seizure 
free period as well controlled seizure.  
 
Implication of non-responders towards treatment 
Pediatric seizure affects not only the life of the child, 
but also the life of the parents. Larson and colleagues 
reported, household with child affected by epilepsy 
tends to have both the child and the parents sleep 
deprived. Furthermore, the author found the severity 
of the epilepsy correlates positively with the both 
child’s and parent’s sleeping dysfunction and 
parental fatigue. 12 Epilepsy also may cause self-
perceived stigma among the patient and this may 
reduce the self-confidence of the person according 
to a cross-sectional study done in Tehran, although 
the author believes the level of stigma may differ 
from region to region.13 And finally, as all other 
chronic illness, pediatric epilepsy does affect the 
family of the child monetarily. The cost burden not 
only limited to the cost to the health system (such as 
drugs, hospitalization, family physician visit etc.) 
but also cost to the individuals and households (out 
of pocket cost and cost associated with treatment) 
and indirect cost (unemployment and loss of 
income). A meta-analysis by Allers and colleagues 
(which includes pediatric epilepsy) shows epilepsy 
does pose substantial economic burden to the 
individuals and the family member .14 
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Antiepileptic drugs 
Generally antiepileptic can be separated into two 
groups based on the drug developmental era; which 
is the first-generation antiepileptic and second-
generation antiepileptic. The first-generation 
antiepileptic is any drugs licenced for treatment of 
epilepsy before 1980. 15 Examples that commonly 
used in Ministry of Health hospitals is Phenytoin, 
Valproate, Carbamazepine and other 
benzodiazepines. The problems usually faced with 
older generation antiepileptic is the enzyme 
inducing and inhibiting properties, which in turn 
potentially can put them in situation where 
interaction will occur with other medications. 15 
The newer antiepileptic used is 
lamotrigine, oxcarbazepine, topiramate, gabapentin, 
felbamate, vigabatrin, levatiracetam, zonisamide, 
and tiagabine. All the new and old generation of 
antiepileptic’s efficacy have been proven in trials, 
although some of the trials is quasi-experimental. 
16,17 The efficacy newer generation antiepileptic is 
not greater than the time-proven remaining old 
generation antiepileptic. This even can be noticed in 
the prescribing pattern of antiepileptic where the old 
generation antiepileptic still predominates.  The 
newer generation however, possess certain 
advantage such as different mechanism which 
enable synergetic combination (in view of old 
generation antiepileptic have troublesome 
interaction). Furthermore, the newer antiepileptic 
has the advantage of lesser congenital malformation. 
18 
This review aimed to look at factors that 
could contribute to control of seizure in pediatric 
patients. 
 
METHODS 
Search for the literature is done using databases such 
as PubMed, Science direct, google scholar and 
Scopus for journals, conference proceedings, and 
systematic reviews related to seizure control in 
pediatric patients on antiepileptic.  
The scope of review was factors related to 
seizure control among pediatric populations taking 
antiepileptic medications. The criteria for this 
review was published articles from 1997 to 2017.  
The following keywords was being used 
such as “seizure control factors AND pediatric 
patients”, “seizure control factors AND children OR 
adolescents”, “seizure response rate factors AND 
pediatric patients” were used to identify the relevant 
journals via the databases.  
All the journals were screened titles and if 
were appropriate were reviewed the abstracts. The 
full text of the selected articles was retrieved if were 
in English. A total of 33 articles includes original 
articles and reviews were obtained for the purpose 
of this review.  
 
RESULTS 
A total of 29 literature has been extracted for the 
literature search. We could divide the factors that 
affect seizure control into three domains, namely; 
sociodemographic factors, medication related 
factors, and genetic factors.  Sociodemographic 
domains can be factors such as age, gender, familial 
income and parental health literacy. On the other 
hand, medication domain can factor such as 
noncompliance and or number of antiepileptics. The 
final domain that we found is the genetic domain. 
Both medication domain and sociodemographic 
status domain contribute the most (each 12 studies) 
of the literature. Certain studies do describe more 
than one domain as affecting seizure control such as 
genetic and medication or sociodemographic status 
and medication. The result of the search can be 
summarized in Table 1. 
 
Table 1 Characteristics of study of factors affecting seizure control in pediatric population 
 
No Author Title Year  Study 
Design 
Domain 
1 McPherson et al Noncompliance with medical follow-up 
after pediatric intensive care. 
2002 Cohort Medication 
2 Zorc et al Predictors of primary care follow-up after 
a pediatric emergency visit for asthma 
2005 Randomize
d Control 
Trial 
Medication 
3 Paula Gardiner & 
Dvorkin, L 
Promoting Medication Adherence in 
Children 
2006 Practice 
statement 
Medication 
4 McCormick et al Emotional functioning, barriers, and 
medication adherence in pediatric 
transplant recipients 
2013 Cross 
Sectional 
Study 
Medication 
5 Hovinga CA et al Association of non-adherence to 
antiepileptic drugs and seizures, quality of 
life, and productivity: survey of patients 
with epilepsy and physicians. 
2008 Cross 
Sectional 
Study 
Medication 
6 Scheffer IE et al Epilepsy genetics revolutionizes clinical 
practice. 
2014 Narrative 
review 
Genetic 
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7 Lin WH et al Seizure control through genetic and 
pharmacological manipulation of Pumilio 
in Drosophila: a key component of 
neuronal homeostasis. 
2017 Narrative 
review 
Genetic 
8 Shorvon S et al Oxford textbook of epilepsy and epileptic 
seizures. 
2012 Textbook 
Chapter 
Genetic 
9 Wirrel EC Treatment of Dravet Syndrome 2016 Narrative 
review 
Genetic 
10 Malik MA et al Predictors of intractable childhood 
epilepsy.  
2008 Cross 
Sectional 
Study 
SD status & 
Genetic 
11 Berkovic SF Genetics of Epilepsy in Clinical Practice. 2015 Narrative 
review 
Genetic 
12 Holmes GL Epilepsy in the developing brain: lessons 
from the laboratory and clinic. Epilepsia. 
1997 Narrative 
review 
SD status 
13 Wyllie E Developmental aspects of seizure 
semiology: problems in identifying 
localized‐onset seizures in infants and 
children 
1995 Narrative 
review 
SD status 
14 Poudel P Predictors of poor seizure control in 
children managed at a tertiary care 
hospital of Eastern Nepal 
2016 Cross 
Sectional 
Study 
SD status & 
Medication 
15 Berg AT Predictors of intractable epilepsy in 
childhood: a case‐control study 
1996 Case-
control 
study 
SD status 
16 Wirrell E Predictors and course of medically 
intractable epilepsy in young children 
presenting before 36 months of age: A 
retrospective, population‐based study. 
2012 Cohort SD status 
17 Christensen J Gender differences in epilepsy 2005 Cross 
Sectional 
Study 
Gender 
18 Begley C Socioeconomic status, health care use, 
and outcomes: persistence of disparities 
over time. 
2011 Cohort SD status 
19 Paschal AM Parent health literacy and adherence-
related outcomes in children with 
epilepsy. 
2016 Cross 
Sectional 
Study 
SD status & 
Medication 
20 Sanders LM Literacy and child health: a systematic 
review. 
2009 Systematic 
Review 
SD status 
21 DeWalt DA Health literacy and child health outcomes: 
a systematic review of the literature. 
2009 Systematic 
Review 
SD status 
22 Getnet A, Antiepileptic drug nonadherence and its 
predictors among people with epilepsy. 
2016 Cross 
Sectional 
Study 
Medication 
23 Canevini MP Relationship between adverse effects of 
antiepileptic drugs, number of 
coprescribed drugs, and drug load in a 
large cohort of consecutive patients with 
drug‐refractory epilepsy 
2010 Cross 
Sectional 
Study 
Medication 
24 Hasan SS Antiepileptic drug utilisation and seizure 
outcome among paediatric patients in a 
Malaysian public hospital. 
2010 Cohort Medication 
25 Conn KM Parental beliefs about medications and 
medication adherence among urban 
children with asthma. 
2005 Cross 
Sectional 
Study 
SD Status 
26 Conn KM The impact of parents' medication beliefs 
on asthma management. 
2007 Cross 
Sectional 
Study 
SD Status 
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27 Patsalos PN The importance of drug interactions in 
epilepsy therapy 
2002 Narrative 
Review 
Medication 
28 Buchanan N Medications which may lower seizure 
threshold 
2001 Narrative 
Review 
Medication 
29 Lalic M Lamotrigine and valproate 
pharmacokinetics interactions in epileptic 
patients. 
2009 Randomised 
Control 
Trial 
Medication 
 SD status = Sociodemographic status 
 
Sociodemographic domains 
Age 
The child’s brain when immature is the state where 
its more susceptible to seizures than mature brains 
(adult).30 This statement can be understood by 
observation that, incidence of seizure is highest 
when the child affected is in the early years of life. 
However, this subsequently reduces as the child 
ages.30 This phenomenon can be explained from the 
animal studies; immature animals have lower 
seizure threshold compared with matured animals. 
In such animals, inhibitory systems are lacked 
compared to excitatory system.30 
The manifestations of seizure symptoms 
are influenced by the age. Children with temporal 
lobe epilepsy the age of 6 years old and older tend 
to have presentation which is similar to adult, (auras, 
activity arrest, simple and complex automatisms, 
and dystonic posture) while younger child tend to 
have less complex behaviour. 31 
Irrespective of the type of seizure, most of 
the child (60%) will eventually outgrow their 
epilepsy and discontinue the antiepileptic. 7,31 Such 
patients will be treated with medication up to 2 years 
of fit-free, similar with the adult patients. However, 
there are intractable childhood epilepsy that have 
poor prognosis. Uncontrolled seizure may lead to 
mental retardation, difficulty in learning and 
behavioural problem. 7  
Furthermore, the treatment with 
antiepileptic for child may differ from adults in term 
of effect.7 For example, age has influence of the 
pharmacokinetics of the antiepileptic. Neonates 
commonly will eliminate antiepileptic slower than 
other age group. After neonatal stage, as the child 
grow up, the clearance of antiepileptic drug tends to 
be faster and have wide intra-group variability.7 
Antiepileptic drugs tend to be more harmful to the 
immature brain compared to the matured brain. 
Studies demonstrated that antiepileptic affect 
cognitive and behavioural disturbances in children. 
The adverse effects may continue despite 
discontinuation of the drug. 30 
Poudel and colleagues finds that younger 
age onset of seizure have poor seizure control.32  The 
same finding was also echoed by Berg and 
colleagues through a case control study identifying 
predictors of medically treated intractable epilepsy. 
In the study Berg and colleagues found that cases 
have significantly lower age compared to control 
with the odds ratio of 10.42, p=0.03 .33 Furthermore, 
Berg and colleagues found the risk of getting 
intractable pediatric epilepsy decreases by age with 
odds ratio of 0.77 with p- value less than 0.0001. 
Similar finding also evident in the case-control study 
by Malik and colleagues where seizure at infancy 
has the odds ratio 5.27.28 
 
Gender 
In our literature search, we could not find any 
significant association for gender and seizure 
control. Interestingly Malik and colleagues found 
there is association, where being male, increases the 
odd by 3.92.28 However, the author agrees that there 
are conflicting findings about gender effect on the 
seizure control in other sources. For instance, 
Wirrell and colleagues does not find any statistically 
significant association of gender with seizure 
control. 34 The gender however does have a 
difference in susceptibility in developing certain 
epilepsy subtype. 35 
 
Socioeconomic 
Socioeconomic factors have an important role in 
disease outcome. Any shortcoming in 
socioeconomic factors must be identified to promote 
social equity. In a study by Begley and colleagues, 
they found out that general epilepsy patient’s 
population from lower socioeconomic strata have 
higher rate of hospitalization and emergency 
department visit. The population also tend to 
experience greater like hood of getting uncontrolled 
seizure, drug related side effects, stigmatized and 
have poor quality of life.36 
As for the pediatric seizure, the same 
outcome could be expected as socioeconomic of 
adult parents will affect the child. Iqbal and 
colleagues conducted a study examining the effect 
of parental education on the quality of life and 
general health of epilepsy children. The shows 
parental education, plays a significant role in general 
health and overall quality of life of the epileptic 
child.37 
Another component of socioeconomic 
factor is household income. Adequate house hold 
income reflects adequate quality of life. A study by 
Paschal and colleagues found that household income 
is a predictor for less miss dose. 38 
 
Parental health literacy 
Parental health literacy plays an important point in 
seizure control. Since most epileptic child will be 
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taken care by the parents, it is vital for the parents to 
have an adequate health literacy to provide better 
care for their offspring. In a study by Paschal and 
colleagues, it was noted that, parent’s health literacy 
has an overall predictor for miss dose and seizure 
frequency .38 However, it must be noted the seizure 
frequency in Paschal et al serves just as an arbitrary 
marker as the investigator just asked about the 
seizure frequency in last 30 days and not as the 
definition by International League Against 
Epilepsy.10 
In a systematic review by sanders and 
colleagues, caregiver with low health literacy have 
association with poor preventative behavior and 
poor child health outcome. Furthermore, adults with 
poor health literacy has 1.2 to 4 times tendency to 
exhibit behaviors that promotes bad outcome on 
child’s health.39 
Similar findings were found in another 
systematic review by DeWalt and Hink, that parents 
with low literacy generally have low health 
knowledge and had bad behavior that were less 
advantageous for children compared with parents 
with high literacy. 40 
 
Medication-Related Domain 
1) Noncompliance 
Noncompliance can be divided into 2 categories: 
noncompliance toward treatment and 
noncompliance towards follow up. In a study by 
McPherson and colleagues, in a cohort of 111 
patients who discharged from pediatric PICU, was 
found that the probabilities of being non-compliance 
is increasing by the number of appointments.19 This 
finding is very significant for child epilepsy as the 
child is expected to be seen in neurology clinic for 
quite a long-time till can be weaned off from 
medication (if permissible). And the compliance 
towards the follow up is critically depends on the 
parent’s commitment. In another study by Zorc and 
colleagues, after ED visit for pediatric asthma, only 
55% of the patients went to the primary healthcare 
provider. The factors that affect the decision of 
parents going to the follow-up is lack of 
convenience, long hour waiting at primary 
healthcare provider clinic, and “perceived severity” 
of illness. 20 To date, there is still no studies that 
examines the association of follow-up and epilepsy 
control. 
Poor adherence to medications is common 
in chronic illness (epilepsy, cystic fibrosis, asthma, 
diabetes).21  McCormick King and colleagues 
suggest from their study, among the barriers towards 
their pediatric subjects and parents towards 
adherence to medication is hassle in life, stress and 
common family conflict 22. In a study by Hovinga 
and colleagues, the level of adherence in all epilepsy 
patient taking medication is 71% with 29% 
nonadherence. The study reported the seizure 
control was 64% and 27% respectively.23 Thus, 
compliance play role in seizure control. 
 
2) Polytherapy 
For most of the epilepsy treatment, monotherapy 
will be used to start treatment. In the study of 
medically intractable pediatric seizure patient in 
Nepal, polytherapy is associated with poor seizure 
control .32 The same pattern can be observed in 
Hassan and colleagues' study in Penang, where 
pediatric patient with polytherapy is associated with 
poor seizure control.44 
 
3) Side effect of antiepileptics 
In a cross-sectional study by Getnet and colleagues, 
the odds ratio of a person who experience side 
effects of epilepsy to be noncompliant to medication 
is 1.70 and probably the commonest reason to stop 
medication without consulting doctor. 41 
However, the probability of patient getting 
side effects is based on individual susceptibility 
rather than number of antiepileptics. 42 
A study in Malaysia shows that HLA-
B*1502 is strongly associated with Carbamazepine-
induced Toxic Epidermal Necrosis/Steven Johnson 
Syndrome in the Malay population in Malaysia, as 
already been demonstrated in Han Chinese in 
Taiwan. 43 However, there is no local study linking 
side effects and non-compliance of the 
antiepileptics. 
 
Genetic Domain 
The Field of epilepsy genetic has seen many 
developments since the discovery of the first 
epilepsy gene in the last 22 years ago .24  As we 
already discussed about the seizure control in 
pediatric is 60-70%, roughly one third of those who 
do not respond to treatment can be attributed to the 
genetic cause. 25 For instance, the well-known 
genetic cause of the genetic influence of pediatric 
seizure is Dravet syndrome which begin after 6 
months .26 Dravet syndrome unlike other epilepsy 
syndrome can only be treated by Clobazam, 
Valproate, and Topiramate. 27 
Genetic factor by itself can predict the 
likelihood of family members to develop epilepsy. 
For instant if one has Genetic Generalized Epilepsy 
(GGE), his or her first-degree family members have 
8 times more risk of developing the disease 
compared to general population .24 However, in a 
case control of Malik and colleagues, it was noted 
that family history does not statistically predict the 
odds of having intractable seizure .28. These findings 
may imply that a precise genetic marker need to be 
established from blood test to predict the like hood 
of getting intractable epilepsy rather than just asking 
for family history. As we already discussed before, 
the etiology of seizure may differ in adult population 
with child, thus more detailed history has to be asked 
to determine the genetic effect in our population.  
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With all the advances in the field of epileptic 
genetic, targeted therapy may be expected to be 
trending and may lead to the development of novel 
therapies in years to come. 29 
 
DISCUSSION 
From this review of literature, we can say that there 
are few areas of research which has been well 
studied in other pediatric diseases such as childhood 
asthma but not in pediatric epilepsy.  The areas that 
need further research in pediatric epilepsy is 
unaddressed parental concern on the treatment of 
antiepileptic, parental belief on medication, and 
effect of drug-drug interactions. These factors can 
play a critical role in ensuring compliance in 
treatment. 
In a study by Conn and colleagues, 67 
asthmatic children’s (on controller medication) 
parents were interviewed. Only 22% of the parents 
is completely complaint while 34% of the parents 
were having strong concern about the medication 
(fear of unknown medication side effects). The 
parents with strong concern about the medication 
was associated with poor compliance towards the 
medication. 45 In another study by Conn and 
colleagues 2 years later, this time to assess parental 
the effect of perception necessity versus concern on 
the medication. Surprisingly the study shows parents 
with necessity index higher than concern, tend to 
give better compliance results than otherwise. 46 
Parental concerns should be addressed 
clearly during prescribing or dispensing medication 
to prevent noncompliance. For instance, the parents 
could stop giving medication for chronic illness if 
he/she felt the patient is well (in this case stop 
medication when not fitting) to reduce the like hood 
to get adverse drug effects. 21 
The drug-drug interactions in epilepsy 
regimes may have both beneficial or harmful effect. 
The beneficial effects would lead to enhancing 
therapeutic potential. On the other hand, the harmful 
effect will be increase in adverse effect or reduced 
efficacy. 50 This effect is more prominent in old 
generation antiepileptic due to enzyme inducing and 
inhibiting effects. Other than antiepileptic itself, 
there are other medications that could potentially 
reduce seizure threshold, increasing the chance of 
the patient to get seizure. Medications such as 
propofol, certain antibiotics (penicillin, 
cephalosporin, imipenem, amphotericin), and 
clozapine. 51 
Among the group of patients particularly 
vulnerable to the drug interactions in epilepsy is 
those with genetic polymorphism, elderly, children, 
and pregnancy. The child especially is vulnerable 
because they can metabolize drugs faster than 
adults. Certain medication such as lamotrigine have 
high inter-individual variability depending of the 
age of child and co-administered antiepileptic .50  
Lamotrigine’s metabolism can be inhibited by 
valproate, thus increasing serum level of 
lamotrigine. 52  This may potentiate the side effect of 
getting serious rash that leads to hospitalization 
(Steven Johnson syndrome). The monitoring of 
blood level of lamotrigine is not possible in 
Malaysia, due to unavailable reagent for therapeutic 
drug monitoring.  
Interestingly, we found that the factors are 
not mutually exclusive. For example, study by study 
by Paschal and colleagues, it was noted that, 
parent’s health literacy has an overall predictor for 
miss dose and seizure frequency. Furthermore, study 
by Paudel shows that polytherapy is associated with 
poor seizure control as well. The reason maybe high 
pill burden leads to noncompliance. Thus, for future 
study, researchers should keep into consideration of 
these possible confounding effects of the factors.  
 
CONCLUSION 
Pediatric seizure control is contributed by many 
factors. Further studies should be done to ascertain 
factors which is less studied. Factors such as 
unaddressed parental concern on the treatment of 
antiepileptic/parental belief on medication, denial of 
the disease on the epilepsy treatment, and effect of 
drug-drug interactions is less studied on the control 
of seizure in pediatric. 
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